Linagliptin 2.5 and 5mg tab
Indicated to treat type 2 diabetes
Inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme which is involved in the inactivation of the incretin hormones GLP-1 and GIP. Both incretin hormones are involved in the physiological regulation of the glucose homeostasis. Inhibition of DPP4 leads to increased and prolonged active incretin levels.
Half-life is 12 hrs with bioavailability 30%. 90% of the dose is excreted unchanged and eliminated via enterohepatic circulation.
5mg once daily is recommended. It can be taken irrespective of food intake.
Each strip of Incret contains 10 tablets in a box of 10 x 10s.